Steven M. Dinh
Geen lopende functies
Profiel
Steven M.
Dinh joined Emisphere Technologies, Inc. in 1999 and serves as Vice President of Research Technology and Development.
He has been Chief Scientific Officer and Vice President of Noven Pharmaceuticals, Inc. since June 6, 2008.
Previously, Dr. Dinh was Vice President and Chief Scientific Officer with Lavipharm Pharmaceuticals, Inc. Prior to joining Emisphere, he held various research positions in transdermal product development and basic pharmaceutics research with Novartis Pharmaceuticals Corp., CIBA-Geigy Corporation and E.
I.
DuPont de Nemours & Co. Dr. Dinh received a Doctor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology.
Eerdere bekende functies van Steven M. Dinh
| Bedrijven | Functie | Einde |
|---|---|---|
| EMISPHERE TECHNOLOGIES, INC. | Hoofd Techniek/Wetenschap/O&O | 31-08-2007 |
| AXM PHARMA, INC. | Directeur/Bestuurslid | 23-08-2006 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Hoofd Techniek/Wetenschap/O&O | - |
| Lavipharm Laboratories, Inc. | Hoofd Techniek/Wetenschap/O&O | - |
Cordex Pharma, Inc.
 Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | Directeur/Bestuurslid | - |
Opleiding van Steven M. Dinh
| Massachusetts Institute of Technology | Doctorate Degree |
| Cornell University | Graduate Degree |
| The Cooper Union for the Advancement of Science & Art | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AXM PHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Emisphere Technologies, Inc.
 Emisphere Technologies, Inc. Pharmaceuticals: MajorHealth Technology Emisphere Technologies, Inc. is a commercial stage specialty pharmaceutical company, which engages in the development of new formulations of existing products and chemical entities, using Eligen Technology. Its product pipelines include eligen B12, eligen12.com, eligen B12 information, and purchase eligen B12. The company was founded in 1986 and is headquartered in Roseland, NJ. | Health Technology |
Cordex Pharma, Inc.
Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
| Lavipharm Laboratories, Inc. |
